Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
ConditionHepatocarcinoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorHua Li
About this trial
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after resection.
Eligibility criteria
Qualifiers
Age between 18 and 80 years;
ECOG Performance Status (PS) of 0 or 1;
Histologically or cytologically diagnosed as HCC
Fully recovered from surgical resection or ablation prior to enrollment;
Disqualifiers
Known cases of fibrolamellar hepatocellular carcinoma (HCC), sarcomatoid HCC, or mixed cholangiocarcinoma and HCC;
HCC recurrence prior to study enrollment;
Co-infection with HBV and delta hepatitis virus;
Clinically significant ascites (Note: ascites detectable only through imaging studies are permitted to participate in the study);
Trial design
Treatments tested in this trial
- Icariin Soft Capsules+TACE
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Hua Li
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Sponsor institution
Source ClinicalTrials.gov